Pharmaceutical Key Trends 2011 – Socio-Demographic and Economic Overview : Rising healthcare costs coupled with the economic downturn continue to shape the healthcare landscape

Introduction

Aging populations, the growing prevalence of chronic disease, greater use of expensive treatments, and expanding public healthcare coverage in markets such as the US are stretching existing healthcare resources. Healthcare payers are also feeling the impact of the global economic downturn through reduced funding via taxation as a result of rising unemployment.

Features and benefits

* An overview of demographic trends in developed and emerging markets
* Analysis of disease burden in developed and emerging markets
* Insight into the economic trends in developed and developing markets
* Summary of measures taken by governments to reduce healthcare costs

Highlights

The increasingly aging global population, changing dietary habits toward a Western-style diet are key risk factors driving up the prevalence of chronic diseases Nevertheless, earlier intervention, as well as improvements in diagnosis and treatments, is helping to reduce mortality rates in a number of these diseases In the developed markets.
Aging populations and declining numbers of people of working age are stretching public healthcare budgets, an issue that is exacerbated as a result of the global economic downturn. Consequently, a number of countries have or plan to introduce a number of strategies to offset this.
Government cost containment measures such as reducing healthcare budgets (at least in real terms) and implementing pricing and reimbursement cuts, as well as bolstering generic uptake, together with the increasingly tough regulatory environment are already having a negative impact on the pharmaceutical industry

Your key questions answered

* Evaluate key socio-demographic factors driving healthcare expenditure in both developed and emerging markets
* Gain insight into how the economic downturn has impacted the healthcare landscape
* Review the cost-containment measures implemented by governments in developed markets and how these impact the pharma industry
[Studien Infos ausblenden]

Executive Summary
Strategic scoping and focus
Key findings
Key growth drivers and resistors facing healthcare payers and pharma
Disease Burden
Socioeconomic trends
DEMOGRAPHIC TRENDS ANALYSIS
Demographic trends in the major developed and emerging markets
Population growth rates in the 12 major markets are slowing
Aging populations are a major strain on healthcare provisions in developed markets
Governments in emerging markets have implemented healthcare reforms to expand healthcare coverage
The key aims of healthcare reforms in developing emerging markets include the following:
Birth rates will continue to fall across most markets
DISEASE BURDEN ANALYSIS
Disease burden
Ischemic heart disease and cerebrovascular disease
Trachea, bronchus and lung cancers
Chronic obstructive pulmonary disease
Lower respiratory tract infections
Colon and rectum cancers
Alzheimer’s disease
Diabetes mellitus type 1 and 2
Stomach cancer
Breast cancer
Diseases associated with poverty are still rife in emerging markets
ECONOMIC TRENDS ANALYSIS
Impact of the economic downturn on both developed and emerging markets
A background to the economic crisis
Debt trap analysis
Government strategies to cut the budget deficit
EU economies have looked to make public spending cuts in order to reduce budget deficits
Unpaid liabilities and bond yields are both assisting and threatening US economic recovery
Japan’s budget deficit is projected to reach almost 10% of GDP in 2010
Australia has been less affected by the downturn than other OECD countries
Developing markets with weaker ties to the West were less affected by the global economic crisis
The impact of the economic downturn on the pharmaceutical industry
Countries are containing healthcare costs in order to help reduce their budget deficits
Pharmaceuticals are a key target for government healthcare spending cuts
Government strategies to contain healthcare and pharmaceutical costs
Healthcare spending has slowed in several markets as governments bring in austerity measures
Pricing and reimbursement cuts were key elements included in austerity measures in many developed markets
Driving generic uptake will create further savingsIn addition to pricing and reimbursement cuts, many governments have recently introduced or modified existing measures in order to enhance generic uptake. These include:
BIBLIOGRAPHY
Publications and online articles
Datamonitor reports and products
APPENDIX
Exchange rates used in this report
[Inhaltsverzeichnis ausblenden]